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Abstract
Background: Endothelin-1 (ET-1) and Nitric Oxide (NO) are crucial mediators for establishing
pulmonary artery hypertension (PAH). We tested the hypothesis that their imbalance might also
occur in COPD patients with PAH.
Methods: The aims of the study were to measure exhaled breath condensate (EBC) and
circulating levels of ET-1, as well as exhaled NO (FENO) levels by, respectively, a specific enzyme
immunoassay kit, and by chemiluminescence analysis in 3 groups of subjects: COPD with PAH (12),
COPD only (36), and healthy individuals (15). In order to evaluate pulmonary-artery systolic
pressure (PaPs), all COPD patients underwent Echo-Doppler assessment.
Results: Significantly increased exhaled and circulating levels of ET-1 were found in COPD with
PAH compared to both COPD (p < 0.0001) only, and healthy controls (p < 0.0001). In COPD with
PAH, linear regression analysis showed good correlation between ET-1 in EBC and PaPs (r = 0.621;
p = 0.031), and between arterial levels of ET-1 and PaPs (r = 0.648; p = 0.022), while arterial levels
of ET-1 inversely correlated with FEV1%, (r = -0.59, p = 0.043), and PaPs negatively correlated to
PaO2 (r = -0.618; p = 0.032). Significantly reduced levels of FENO were found in COPD associated
with PAH, compared to COPD only (22.92 ± 11.38 vs.35.07 ± 17.53 ppb; p = 0.03). Thus, we
observed an imbalanced output in the breath between ET-1 and NO, as expression of pulmonary
endothelium and epithelium impairment, in COPD with PAH compared to COPD only. Whether
this imbalance is an early cause or result of PAH due to COPD is still unknown and deserves further
investigations.
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Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of morbidity and mortality in devel-
oped countries. Pulmonary artery hypertension (PAH),
frequently observed in patients with advanced COPD, is
considered a predictor of worse outcome [1,2]. PAH in
COPD is mainly the result of hypoxic pulmonary vaso-
constriction [3], however it has been recently shown also
induced by pulmonary arterial walls remodelling, with
aberrant intimal changes [4,5]. Further evidences suggest
that the initial event in the natural history of pulmonary
hypertension due to COPD is the lesion of pulmonary
endothelium by cigarette-smoke products [6,7], leading
to critical changes in the expression of vascular mediators
[7,8], which are responsible for impairment of endothe-
lial function. Among a wide spectrum of vasoactive medi-
ators, endothelin-1 (ET-1) plays a pivotal role in exerting
vasoconstriction [9], bronchoconstriction [10], vascular
[11] and airway [12] cells proliferation, via ETA and ETB
receptors [13,14]. Increased expression of ET-1, it has
been identified in the vessels of patients with IPAH [15].
Plasma [16,17], induced sputum [18], and urinary [17]
levels of ET-1 are augmented in patients with COPD; how-
ever, there are still contrasting data about circulating ET-1
levels in COPD patients with PAH [19-21]. In addition,
no data are yet available on ET-1 levels in exhaled breath
condensate of COPD patients.
Nitric oxide (NO), produced by endothelial cells, is the
central stimulus for releasing and dilating pulmonary
arterial vasculature [22]. NO production is oxygen
dependent and lack of NO synthesis, under hypoxic con-
ditions such as COPD, contributes to chronic hypoxic pul-
monary vasoconstriction [23], leading to pulmonary
artery hypertension [24]. It is now appreciated that NO
release is impaired in the pulmonary vasculature of COPD
patients [25], while exhaled NO levels, increased in
COPD [26], are significantly reduced in COPD associated
with PAH [27]. An imbalance between the excretion of
vascular mediators has been shown important for devel-
oping idiopathic pulmonary hypertension [8] and might
be also responsible in promoting secondary PAH [8]. We
hypothesized a pathological dysregulation of exhaled out-
put between ET-1 and NO in COPD with PAH. Despite
several issues about reproducibility, variability and sensi-
tivity, measurement of different biological markers in
COPD is currently a useful assay in assessing disease
pathogenesis, predicting progression, and monitoring
adequate therapies [28]. The aims of the present study
were to investigate exhaled breath condensate (EBC) and
circulating levels of ET-1, as well as the exhaled NO
(FENO) in COPD only, in COPD with pulmonary artery
hypertension, and in a group of healthy subjects. We also
examined whether concentrations of exhaled biomarkers,
or circulating ET-1 levels were related to the severity of dis-
ease, as defined by lung function, or pulmonary artery
pressure.
Methods
The Institutional Review and the Ethical Boards of the
University of Bari approved protocols and all patients
signed informed consent before participating in this
study.
Patient population
Sixty-three subjects were enrolled into the study at outpa-
tient clinic of Institutes of pulmonary disease, University
of Bari, from March 2004 to January 2007. Subjects were
divided into three groups on the basis of pathological
characteristics. The first group consisted of 12 patients
with COPD (stage III and IV), diagnosed according to the
American Thoracic Society (ATS) criteria [29] (11 males,
mean age 70.8 ± 6.7 years), associated with PAH. All
patients were ex smokers (mean pack-years, 26 ± 7) with-
out a history of atopy and with normal IgE levels. Five
patients had been receiving long-term domiciliary oxygen
for at least 6 consecutive months.
A second group included 36 patients with COPD, diag-
nosed according to the American Thoracic Society (ATS)
criteria (30). All patients (32 males, mean age 67.6 ± 9.2
years) were ex smokers (mean pack-years, 25 ± 6) without
a history of atopy and with normal IgE levels; six patients
had been receiving long-term domiciliary oxygen for at
least 6 consecutive months. 15 healthy non-smoking,
non-atopic subjects (9 males, mean age 58 ± 9.2 years)
were enrolled as controls. Patients with other organ fail-
ure, cancer, or inability to cooperate were excluded from
the study. At the time of inclusion into the study, all the
patients were in stable condition, and free from respira-
tory tract infection and/or acute exacerbation in the pre-
ceding 6 weeks. All of the patients were receiving their
regular treatment with inhaled bronchodilators, but none
was receiving systemic or inhaled steroids. No change in
medical therapy was made in the week prior to the study.
Pulmonary function test and arterial blood gas analysis
Pulmonary function tests were performed in the pulmo-
nary function laboratory of our Institutes at admission to
the study. Static and dynamic lung volumes were meas-
ured by means of a constant-volume body plethysmo-
graph (MasterScreen Body, Jaeger, Germany) and
according to the guidelines of the American Thoracic Soci-
ety (ATS) [30]. The best of three reproducible values was
expressed as a percentage of the predicted normal value.
Arterial blood for the analysis of gases during room air
breathing was drawn in all patients by radial artery in the
supine position and after a 30 minute rest period. PaO2,Page 2 of 10
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(Model 1312; Instrumentation Laboratory; Milan, Italy).
Echo-Doppler assessment
All patients of groups 1-2-3 were investigated using real-
time, phased array, two-dimensional Doppler (2-D)
echocardiography (CFM 750 CV 2.5 or 3.25 MHz trans-
ducer; GE Vingmed, Milan, Italy). The examinations were
taken on patients in a semirecumbent left lateral position,
and images were taken from subxiphoid, parasternal, and
apical views. The mean value of three measurements was
considered. Tricuspid valve regurgitation pressure was
identified by color flow mapping, then, maximal pressure
gradient between right ventricular and right atrial was
obtained using the continuous wave Doppler on the guid-
ance of the color Doppler signal of the tricuspid regurgita-
tion. Peak pressure gradient measurement was estimated
by means of a simplified Bernoulli equation [31]. Pulmo-
nary-artery systolic pressure (PaPs) was calculated by add-
ing the Bernoulli derived pressure gradient to an assumed
right atrial pressure of 10 mmHg. A PaPs ≥ 35 mmHg was
considered as cut-off.
Measurement of ET-1 levels
ET-1 was evaluated in the (EBC) as well as in arterial and
venous blood of all the subjects. ET-1 was obtained by
using a condenser non-invasively to collect the non-gase-
ous components of the expiratory air (EcoScreen: Jaeger,
Würzburg, Germany). Subjects were instructed to breathe
through a mouthpiece and a two-way, non-rebreathing
valve, which also served as a saliva trap, in order to avoid
contamination. They were asked to breathe at tidal vol-
ume, wearing a nose clip, for a period of 10 min. The con-
densate (at least 1 ml) was transferred to centrifuges tubes
and immediately stored at -80°C. Peripheral venous
blood samples were obtained, in all subjects, from an
antecubital vein after at least 30 min seated rest. Venous
blood samples were collected in plastic tube containing
ethylenediamine tetraacetic acid (EDTA), centrifuged at
5000*g for 10 min and plasma was frozen and stored at -
80°C until assay. Arterial blood gas analyses were per-
formed in all subjects, while breathing room air, by radial
artery in the supine position and after a 30 minute rest
period. A specific enzyme immunoassay (EIA) kit (Cay-
man Chemical, Ann Arbor, Mich., USA) was used to meas-
ure ET-1 concentrations in the breath condensate and in
blood samples. The specificity of the test for ET-1 was
100%, and the cut-off of the assay was considered a con-
centration ≥ 1.5 pg/ml. The reproducibility of repeated
ET-1 exhaled condensate measurements was assessed by
the Bland and Altman method [32].
NO measurement
Exhaled NO was measured by a chemiluminescence ana-
lyzer (NOA Tm280; Sievers Instruments Inc., Boulder,
CO, USA) by the on-line single-breath technique, accord-
ing to the ATS and ERS recommendations [33]. Subjects
were asked to perform a single slow exhalation starting
from total lung capacity through a mouthpiece against a
resistance of 16 cm H2O under a visual biofeedback, to
maintain a 50 ml second (s) steady flow. Subjects were at
rest, sitting down, having refrained from eating and exer-
cise for at least 2 hours, and breathed filtered NO-free air
(air filter AFL 01410; Sievers Instruments Inc.) without a
nose-clip before the single exhalation maneuver. Ambient
air NO was recorded before and after each test. FENO lev-
els were measured at the plateau of the end exhaled read-
ing and expressed as parts per billion (ppb). At least three
measurements that varied by <10% or two measurements
that varied by <5% were recorded. Mean values of the
respective plateaux were evaluated.
Six minutes walking test
The 6-min walking distance (6 MWD) test was performed,
at admission to the study, in 6 COPD with PAH, accord-
ing to standard method [34].
Statistical analysis
Data are presented as mean value ± standard deviation
(SD). As the data presented normal distribution (Kol-
mogorov-Smirnov test), parametric tests were used for sta-
tistical analysis. Analysis of variance (ANOVA) was used
to perform comparisons between groups. Relationships
between patients' characteristics were evaluated using
Pearson correlation coefficients. Comparisons of means ±
SD among the groups were made by an unpaired t-test.
Significance was established at a p-value < 0.05. StatView
version 5.0 (SAS Institute, Cary, N.C., USA) was used for
the statistical analysis. Both, correlations between clinical
parameters and exhaled or circulating levels of ET-1 pre-
sented as scattered plots, and exhaled levels of ET-1 and
NO expressed as bar graphs, were made by using Kaleida-
Graph program (Version 3.02, Synergy soft-ware, PA,
USA).
Results
Demographic and clinical characteristics of 63 individuals
recruited are presented in table 1. Endothelin-1 was
detectable in the exhaled breath as well as in the blood of
all subjects. The reproducibility of repeated ET-1 measure-
ments was quite good, and was assessed by the Bland and
Altman method [32] in six patients (mean difference 0.62
± 1.214). NO was detectable in the exhaled of all individ-
uals. All COPD patients were investigated with Echo-Dop-
pler and then assigned to one of two groups according to
the level of PaPs, using a cut-off of 35 mmHg. Those with
a PaPs ≥ 35 mmHg (Group 1: N = 12; FEV1% 39.35 ±
11.45; PaPs 51.08 ± 12.21 mmHg), and those with a PaPs
< 35 mmHg (Group 2: N = 36; FEV1% 48.13 ± 18.04; PaPs
26.05 ± 3.39 mmHg).Page 3 of 10
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Significantly increased levels of ET-1 in EBC were found in
all 12 patients with PAH associated with COPD (FEV1%
39.35 ± 11.45, FEV1/FVC% 46.95 ± 6.81, PaPs ≥ 35
mmHg) (group 1) compared to both COPD only (group
2) (22.36 ± 4 vs 7.25 ± 0.23 pg/ml; p < 0.0001) and to the
control subjects (group 3) (5.24 ± 0.47 pg/ml; p < 0.0001)
(Figure 1). Higher circulating levels of ET-1 both in the
arterial and in the venous sample were found in group 1
compared to all other groups. Arterial levels were
increased as compared to group 2 (12.41 ± 2.13 vs 7.22 ±
0.21 pg/ml; p < 0.0001) and to the controls (0.84 ± 0.37
pg/ml; p < 0.0001) (Figure 2). We also observed increased
levels of ET-1 in the venous blood statistically significant
compared to both group 2 (14.53 ± 2.76 vs 7.29 ± 0.16
pg/ml; p < 0.0001), and to the control group (1 ± 0.42 pg/
ml; p < 0.0001) (Figure 3). Thus, significantly over-expres-
sion of ET-1 was found in COPD with PAH compared to
COPD only. With regards to disease severity, in COPD
with PAH, Pearson correlation analysis showed a good
relationship between ET-1 in EBC and pulmonary-artery
systolic pressure (PaPs) (r = 0.621; p = 0.031) (Figure 4);
A positive correlation was also observed between arterial
blood levels of ET-1 and PaPs (r = 0.648; p = 0.022) (Fig-
ure 5), while the arterial blood levels of ET-1 inversely cor-
related to the FEV1% of the group 1 (r = -0.59, p = 0.043)
(Figure 6). Furthermore, PaPs inversely correlated with
PaO2 in this group of patients (r = -0.618; p = 0.032) (Fig-
ure 7). ET-1 levels in venous blood, although higher than
arterial levels (14.53 ± 2.76 vs. 12.41 ± 2.13), did not cor-
relate with any parameter considered in this group of
patients.
Table 1: Demographic and clinical characteristics of 63 individuals recruited classified in 3 groups. 
Group ofCOPD+PAH (n = 12) Group of COPD (n = 36) Group of HS (n = 15)
Sex, M/F 11/1 32/4 9/6
Age, Years 70.8 (6.7) 67.6 (9.2) 58 (9.2)
Smoking, pack-years 27 (7) 25 (6) 0
FEV1% 39.35 (11.45) 48.13 (18.04) 98.05 (11.65)
FVC% 64.89 (14.90) 69.39 (19.1) 95.07 (13.34)
FEV1/FVC % 46.95 (6.81) 54.27 (12.46) 101.37 (8.5)
RV% 151 (38) 143 (32) 108 (11)
PaO2 (mmHg) 60.83 (4.76) 64.58 (6.16) 97.2 (0.7)
PaCO2 (mmHg) 39.4 (4.27) 41.78 (5.01) 38.4 (1.5)
PaPs (mmHg) 51.08 (12.2)* 26.05 (3.39) NA
ET-1 EBC (pg/ml) 22.36 (4) 7.25 (0.23) 5.24 (0.47)
ET-1 art (pg/ml) 12.41 (2.13) 7.22 (0.21) 0.84 (0.37)
ET-1 ven (pg/ml) 14.53 (2.76) 7.29 (0.16) 1 (0.42)
FENO (ppb) 22.92 (11.38) 35.07 (17.53) 20.56 (3.67)
6MWD 383 (34)§ NA NA
Pulmonary function, arterial blood gases, pulmonary-artery systolic pressure, exhaled breath condensate counts and circulating levels are expressed 
in table 1. Statistical significant difference was found between groups 1 and 2 in pulmonary-artery systolic pressure, PaPs (p < 0.0001).
Definition of abbreviations
EBC: Exhaled Breath Condensate, ET-1: Endothelin-1, FENO: Exhaled Nitric Oxide, FEV1: Forced Expiratory Volume in the first second, FVC: 
Forced Vital Capacity, HS: Healthy Subjects, NO: Nitric Oxide, PAH: Pulmonary Artery Hypertension, RV: Residual Volume, PaPs: Pulmonary-
artery systolic pressure, 6MWD: 6-minutes walking distance
Data are presented as mean (± SD)
NA = not applicable
§ n = 6 patients
* Significant difference compared to COPD group: p < 0.001
Endothelin-1 (expressed as pg/ml) concentration in EBC of the 3 groups: COPD (36), COPD + PAH (12), and healthy subjects (HS) (15)Figure 1
Endothelin-1 (expressed as pg/ml) concentration in 
EBC of the 3 groups: COPD (36), COPD + PAH (12), 
and healthy subjects (HS) (15). Significance was estab-
lished at a p value < 0.05. The horizontal lines represent 
median value. ET-1 in EBC was increased in all COPD 
patients compared to control group (p < 0.0001). In 
COPD+PAH group, ET-1 levels were significantly increased 
compared to both the COPD only and the control group (p 
< 0.0001).
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BMC Pulmonary Medicine 2008, 8:20 http://www.biomedcentral.com/1471-2466/8/20In COPD patients with PAH, we found significantly
reduced levels of FENO compared to COPD only (22.92 ±
11.38 vs.35.07 ± 17.53 ppb; p = 0.03) (Figure 8). These
levels were not different compared to the FENO levels of
the control group (20.56 ± 3.67 ppb; p = 0.45) (Figure 8).
An imbalanced output in the breath between ET-1 and
NO was seen in this group of patients. As shown in figure
9, ET-1 levels were significantly increased in COPD with
PAH compared to COPD only (p < 0.0001), while FENO
levels in group 1 were significantly lower than group 2 lev-
els (p = 0.03). FENO levels did not significantly correlate
with any clinical feature.
Group of COPD only
In 36 COPD patients (FEV1% 48.13 ± 18.04, FEV1/FVC%
54.27 ± 12.46, PaPs <35 mmHg) ET-1 levels in EBC were
significantly higher than control group levels (5.24 ± 0.47
pg/ml; p < 0.0001) (Figure 1). Increased concentrations of
ET-1 in the arterial, as well as in the venous blood, com-
pared to the control group, were found in group 2 (7.22 ±
0.21 vs. 0.84 ± 0.37 pg/ml; p < 0.0001; 7.29 ± 0.16 pg/ml
vs. 1.00 ± 0.42 pg/ml; p < 0.0001) (Figures 2, 3). FENO
levels in COPD were statistically significant higher than
control group levels (35.07 ± 17.53 vs. 20.56 ± 3.67 ppb;
p = 0.003), (Figure 8). Two COPD patients showed higher
NO levels, similar to those detected in asthma and not in
COPD, but we excluded that those levels were related to
an atopic status, on the basis of the IgE total concentra-
Endothelin-1 (expressed as pg/ml) levels in the arterial blood of the 3 groups: COPD (36), COPD + PAH (12), and healthysubjects (HS) (15)Figure 2
Endothelin-1 (expressed as pg/ml) levels in the arte-
rial blood of the 3 groups: COPD (36), COPD + PAH 
(12), and healthy subjects (HS) (15). Significance was 
established at a p value < 0.05. The horizontal lines represent 
median value. ET-1 in arterial sample was increased in all 
COPD patients compared to control group (p < 0.0001). In 
COPD+PAH group, ET-1 levels were significantly increased 
compared to both the COPD only and healthy controls (p < 
0.0001).
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Endothelin-1 (expressed as pg/ml) concentration in the ven us blood of th  3 grou s: COPD (36), COPD + PAH (12), and healthy subjects (HS) (15)Figure 3
Endothelin-1 (expressed as pg/ml) concentration in 
the venous blood of the 3 groups: COPD (36), COPD 
+ PAH (12), and healthy subjects (HS) (15). Signifi-
cance was established at a p value < 0.05. The horizontal 
lines represent median value. ET-1 in venous sample was 
increased in all COPD patients compared to control group 
(p < 0.0001). In COPD+PAH group, ET-1 levels were signifi-
cantly increased compared to both the COPD only and the 
controls (p < 0.0001).
COPD
(36)
COPD+PAH
(12)
HS
(15)
0
5
10
15
20
25 **
*
En
do
th
el
in
-
1 
(p
g/
m
l)
** p<0.0001 vs all
*  p<0.0001 vs HS
COPD+PAH: linear regression shows good correlation between ET-1 levels in the EBC and PaPs (N = 12; r = 0.621; p = 0.031)Figur  4
COPD+PAH: linear regression shows good correla-
tion between ET-1 levels in the EBC and PaPs (N = 
12; r = 0.621; p = 0.031).
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COPD+PAH: positive correlation between arterial blood levels of ET-1 and PaPs (N = 12, r = 0.65; p = 0.022)Figure 5
COPD+PAH: positive correlation between arterial 
blood levels of ET-1 and PaPs (N = 12, r = 0.65; p = 
0.022).
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COPD+PAH: negative correlation between FEV1% and arte-rial blood levels of ET-1 (N = 12, r = -0.59, p = 0.043)Figure 6
COPD+PAH: negative correlation between FEV1% 
and arterial blood levels of ET-1 (N = 12, r = -0.59, p = 
0.043).
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COPD+PAH: negative correlation between PaPs and PaO2 (N = 12, r = -0.618; p = 0.032)Figure 7
COPD+PAH: negative correlation between PaPs and 
PaO2 (N = 12, r = -0.618; p = 0.032).
30
40
50
60
70
80
45 50 55 60 65 70
N=12, R= -0.618; p=0.032
Pa
Ps
(m
m
H
g)
PaO2  (mmHg)
Exhaled nitric oxide concentrations (FENO), expressed as ppm, in 3 g oups: COPD (36), COPD+PAH (12), and healthy subjects (HS) (15)Figure 8
Exhaled nitric oxide concentrations (FENO), 
expressed as ppm, in 3 groups: COPD (36), 
COPD+PAH (12), and healthy subjects (HS) (15). Sig-
nificance was established at a p value < 0.05. The horizontal 
lines represent median value. FENO levels were significantly 
higher in COPD only, compared to both the COPD with 
PAH (p = 0.03), and the controls (p = 0.003). There was no 
significant relationship between FENO levels in COPD+PAH 
compared to the control group levels (p = 0.45).
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BMC Pulmonary Medicine 2008, 8:20 http://www.biomedcentral.com/1471-2466/8/20tion. ET-1 and NO levels did not significantly correlate to
any baseline characteristic in this group of patients.
Discussion
In the natural history of COPD, right heart failure leading
to increased pulmonary artery pressure is a common find-
ing [35,36]. PAH, in this scenario, is likely due to a pri-
mary hypoxic vasoconstriction associated to the direct
toxic effect of tobacco smoke into the intrapulmonary ves-
sels, with abnormal production of substances that control
vasoconstriction, vasodilatation, and vascular cell prolif-
eration, ultimately leading to extensive pulmonary artery
remodelling [2,37]. Early detection of an imbalanced out-
put between essential mediators, such as endothelin-1
and NO, might be a novel approach to rapidly investigate
and eventually treat this critical disease. The present study
was designed to investigate endothelin-1 and NO concen-
tration in the exhaled breath, as well as circulating levels
of ET-1 in COPD patients with or without pulmonary
hypertension. Our findings show that endothelin-1 levels
in EBC are increased in all COPD patients. In addition, we
observed ET-1 levels in EBC significantly higher in COPD
associated with PAH, compared to COPD only. Several
previous studies detected elevated levels of ET-1 in EBC in
interstitial pulmonary disease [38], in non small cell lung
cancer patients (NSCLC) [39], and in unstable bronchial
asthma [40], similar to those observed in our COPD
patients, while in the present, we found significantly
higher EBC levels of ET-1 in COPD with PAH. Carpag-
nano and colleagues hypothesized that ET-1, in patholog-
ical conditions (interstitial pulmonary disease and
NSCLC), could be in part produced by airway epithelium
itself [38,39], while the reason of an exaggerated ET-1
release in EBC in COPD with PAH is still unknown. How-
ever, it appears that ET-1, primary produced by the pul-
monary endothelium, could be in part generated by the
epithelium, and, in addition, could be partially the result
of an uptake into the airway epithelium. Furthermore, we
An imbalance between exhaled condensate ET-1 concentrations and exhaled nitric oxide concentrations (FENO) in COPD (36), and i  COPD+PAH (12)Figure 9
An imbalance between exhaled condensate ET-1 concentrations and exhaled nitric oxide concentrations 
(FENO) in COPD (36), and in COPD+PAH (12). In COPD+PAH group, ET-1 levels were significantly increased com-
pared to the COPD only (p < 0.0001). FENO levels were significantly higher in COPD only, compared to both the COPD with 
PAH (p = 0.03).
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BMC Pulmonary Medicine 2008, 8:20 http://www.biomedcentral.com/1471-2466/8/20found elevated circulating levels of ET-1 in arterial and
venous samples in COPD, and significantly higher levels
in COPD with PAH. Increased circulating ET-1 levels have
been recently shown in exacerbation of COPD [41],
whereas there are still controversial data about ET-1 levels
in the blood of patients with PAH associated with COPD
or emphysema [19-21]. While a study disclosed increased
levels of ET-1 only in pulmonary arterial sample [19], two
reports showed persistent increased circulating ET-1 lev-
els, which correlated to the severity of pulmonary hyper-
tension [20,21]. In our group of COPD patients with
PAH, ET-1 levels in arterial sample positively correlated
with PaPs, however we provide new evidence that also ET-
1 in EBC is related to PaPs. Interestingly, in the same
group, we observed a negative correlation between ET-1
levels in arterial blood and FEV1%, but not between ET-1
levels in EBC and FEV1%. This finding sustains the previ-
ous hypothesis that pulmonary endothelium represents
the mayor source of ET-1, which could be only in part pro-
duced by the airway epithelium, where it may contribute
to induce partial bronchoconstriction, although the latter
observation needs to be validated by further histological
evidences. As previously demonstrated [42], an inverse
correlation between PaPs and PaO2 was observed in this
group, confirming that pulmonary artery pressure and
PaO2 are closely negatively related in PAH induced by
COPD. Regarding to exhaled NO, we found reduced levels
of FENO in COPD with PAH compared to the group of
COPD. Clini and co-workers previously showed reduced
levels of FENO in PAH induced by COPD compared to
COPD only, which negatively correlated with PaPs [27].
In our experience, FENO levels were also significantly
lower in these patients, but we failed to find correlation
with Echo-Doppler assessment. In summary, we observed
a pathological dysregulation output in the breath between
ET-1 and NO in COPD with PAH. Whether the imbalance
in the release of these two mediators is an early cause or
result of pulmonary hypertension due to COPD is
unknown, however the easy and quick detection by a non-
invasive and useful assay might encourage further investi-
gations.
This study has different limitations, likely due to method-
ological assays. First, the control group consisted by
healthy non smokers, and not by ex-smokers with no air-
flow obstruction, that would have been represented a bet-
ter control group. However our COPD patients were all
non smokers from at least 1 year, we consider that smok-
ing habit might not have significantly influenced exhaled
breath results. Second, in COPD patients, the pulmonary
arterial pressure was evaluated by echocardiography anal-
ysis, which does not correspond to the gold standard;
however in 4 patients was previously performed a right
heart catheterization and the results were comparable
with the echo Doppler assessment. Moreover, although
no COPD patient was under steroid treatment, we could
not exclude that other treatments, such as antihyperten-
sive, nitro-derivate, or other drugs, might have influenced
the results. Finally, no significant difference in the treat-
ment between COPD and COPD with pulmonary hyper-
tension was evident.
Conclusion
In conclusion, we found increased expression of ET-1 in
EBC and in the blood, in COPD patients with PAH com-
pared to COPD only. ET-1 levels, both in EBC and in the
arterial samples, positively correlated to pulmonary-artery
systolic pressure, while arterial concentration of ET-1 neg-
atively correlated with FEV1%, indicating that enhanced
ET-1 levels in biological sample might early occur in PAH
secondary to COPD, and actively participate in stimulat-
ing vascular and airway remodelling, through an endog-
enous increased production by the endothelium, and by a
partial release and uptake into the airway epithelium.
Finally, we showed an imbalance output in the breath
between ET-1 and NO in this group of patients, suggesting
that suppression of NO, in pulmonary hypertension,
might have been caused in part by ET-1 [43]. Although the
novel treatment for pulmonary artery hypertension has
been used successfully for IPAH, it remains to be investi-
gated with randomized multicentric studies whether this
new therapy could provide beneficial clinical effects in
PAH secondary to COPD.
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